

## Significance of Acetylcholine Receptor Antibody Titers in Acetylcholine Receptor Antibody-Positive Ocular Myasthenia Gravis: Generalization and Presence of Thyroid Autoimmune Antibodies and Thymoma [Corrigendum]

Supawongwattana M, Vanikieti K, Jindahra P, Padungkiatsagul T. *Clin Ophthalmol*. 2023;17:649–656.

Page 650, Subject Selection section, third line, the text “from January 2012 to June 2022” should be removed.

Page 651, Statistical Analysis section, second sentence, the text “Independent *t*-test or Mann–Whitney *U*-test, where appropriate, were used to compare continuous variables.” should be removed.

Page 651, Statistical Analysis section, fourth sentence, the text “These variables were compared using Chi-squared or exact test where appropriate.” should be removed.

Page 651, Statistical Analysis section, sixth sentence, the text “For multivariate analysis, logistic regression was applied, to simultaneously regress outcomes with variables whose *p*-values in univariate analysis were  $<0.1$ ” should read “For multivariate analysis, logistic regression was applied, to simultaneously regress outcomes with variables whose *p*-values in univariate analysis were  $<0.05$ ”.

Page 651, Statistical Analysis section, seventh sentence, the text “The likelihood ratio test was applied to select and retain only significant variables in the final equation.” should be removed.

Pages 651–652, Results section, third paragraph, third sentence, the text “Given the higher incidence and prevalence of autoimmune diseases in females and more evidence of thymoma producing various autoantibodies,<sup>12,13</sup> these two factors were also included in the multivariate analysis despite their *p*-values of  $>0.1$  in univariate analysis” should read “Given the higher incidence and prevalence of autoimmune diseases in females and more evidence of thymoma producing various autoantibodies,<sup>12,13</sup> these two factors were also included in the multivariate analysis despite their *p*-values of  $\geq 0.05$  in univariate analysis”.

Table 2 on page 653, Univariate Analysis column, the OR (95% CI) and the *p*-value for the  $\geq 8.11$  nmol/L and Positive ice-pack test, n of subjects/n of subjects with available data (%) rows are incorrect.

The correct Table 2 is as follows.

**Table 2** Factors Associated with Conversion to GMG

Variables	Pure OMG	GMG Conversion	Univariate Analysis		Multivariate Analysis	
			OR (95% CI)	p-value	OR (95% CI)	p-value
n of subjects (%)	99 (83.90)	19 (16.10)				
AChR antibody titer, n of subjects (%)						
≥ 8.11 nmol/L	30 (30.30)	13 (68.42)	4.98 (1.73, 14.36)	0.003*	3.66 (1.19, 11.26)	0.023*
< 8.11 nmol/L	69 (69.70)	6 (31.58)	1			
Demographic data						
Age at onset, mean (SD), years	55.7 (16.6)	57.7 (18.8)	1.01 (0.98, 1.04)	0.636		
Sex, female, n of subjects (%)	60 (60.61)	13 (68.42)	1.41 (0.49, 4.02)	0.522		
Hypertension, n of subjects (%)	30 (30.30)	9 (47.37)	2.07 (0.76, 5.61)	0.153		
Diabetes mellitus, n of subjects (%)	18 (18.18)	5 (26.32)	1.61 (0.51, 5.03)	0.415		
Initial ocular signs, n of subjects (%)						
Moderate-to-severe ptosis	72 (72.73)	18 (94.74)	6.75 (0.86, 53.05)	0.069		
Lid fatigability	59 (59.60)	15 (78.95)	2.54 (0.79, 8.22)	0.119		
Cogan lid twitch	38 (38.38)	12 (63.16)	2.75 (1.00, 7.60)	0.051		
Orbicularis oculi weakness	55 (55.56)	15 (78.95)	3.00 (0.93, 9.69)	0.066		
Duction limitation	31 (31.31)	7 (36.84)	1.27 (0.46, 3.56)	0.637		
Positive ice-pack test, n of subjects/n of subjects with available data (%)	49/88 (55.68)	15/17 (88.24)	5.97 (1.29, 27.68)	0.023*	3.37 (0.60, 18.86)	0.167
Thyroid serology tests, n of subjects/n of subjects with available data (%)						
Abnormal thyroid function tests	3/96 (3.13)	3/19 (15.79)	5.81 (1.07, 31.37)	0.041*	6.09 (1.00, 36.86)	0.051
Presence of thyroid autoimmune antibodies	22/68 (32.35)	4/11 (36.36)	1.19 (0.32, 4.51)	0.793		
Presence of thymoma, n of subjects/n of subjects with available data (%)	7/87 (8.05)	2/19 (10.53)	1.34 (0.26, 7.05)	0.726		
Treatment, n of subjects (%)						
Pyridostigmine alone	63 (63.64)	6 (31.58)	0.26 (0.09, 0.75)	0.013*	0.40 (0.12, 1.37)	0.145
Immunosuppressive treatment	36 (36.36)	13 (68.42)	1			
Follow-up period, median (range), months	14 (3–113)	30 (3–84)	1.00 (0.98, 1.02)	0.796		

**Note:** \*Statistically significant ( $p < 0.05$ ).

**Abbreviations:** GMG, generalized myasthenia gravis; OMG, ocular myasthenia gravis; OR, odds ratio; CI, confidence interval; n, number; AChR, acetylcholine receptor; SD, standard deviation.

Table 4 on page 654, Univariate Analysis column, the OR (95% CI) and the  $p$ -value for the  $\geq 15.12$  nmol/L and Abnormal thyroid function tests, n of subjects (%) rows are incorrect.

The correct Table 4 is as follows.

**Table 4** Factors Associated with the Presence of Thymoma

Variables	Absence of Thymoma	Presence of Thymoma	Univariate Analysis		Multivariate Analysis	
			OR (95% CI)	p-value	OR (95% CI)	p-value
n of subjects (%) <sup>†</sup>	97 (91.51)	9 (8.49)				
AChR antibody titer, n of subjects (%)						
≥ 15.12 nmol/L	15 (15.46)	4 (44.44)	4.37 (1.05, 18.19)	0.043*	4.97 (1.10, 22.48)	0.037*
< 15.12 nmol/L	82 (84.54)	5 (55.56)	1			
Demographic data						
Age at onset, mean (SD), years	55.5 (17.6)	56.2 (13.4)	1.00 (0.96, 1.04)	0.903	1.00 (0.96, 1.04)	0.867
Sex, female, n of subjects (%)	61 (62.89)	5 (55.56)	0.74 (0.19, 2.93)	0.665	0.55 (0.12, 2.44)	0.428
Hypertension, n of subjects (%)	29 (29.90)	5 (55.56)	2.93 (0.73, 11.71)	0.128		
Diabetes mellitus, n of subjects (%)	19 (19.59)	2 (22.22)	1.17 (0.23, 6.10)	0.850		
Initial ocular signs, n of subjects (%)						
Moderate-to-severe ptosis	76 (78.35)	5 (55.56)	0.35 (0.09, 1.40)	0.137		
Lid fatigability	63 (64.95)	5 (55.56)	0.67 (0.17, 2.68)	0.576		
Cogan lid twitch	45 (46.39)	2 (22.22)	0.33 (0.07, 1.67)	0.180		
Orbicularis oculi weakness	56 (57.73)	6 (66.67)	1.46 (0.35, 6.20)	0.605		
Duction limitation	35 (36.08)	1 (11.11)	0.22 (0.03, 1.84)	0.163		
Positive ice-pack test, n of subjects/n of subjects with available data (%)	53/87 (60.92)	7/8 (87.50)	4.49 (0.53, 38.13)	0.169		
Thyroid serology tests						
Abnormal thyroid function tests, n of subjects (%)	6 (6.19)	0 (0.00)	0.74 (0.04, 14.20)	0.842		
Presence of thyroid autoimmune antibodies, n of subjects/n of subjects with available data (%)	25/68 (36.76)	1/5 (20.00)	0.43 (0.05, 4.06)	0.461		

**Notes:** <sup>†</sup>Percentages of 106 subjects with available thoracic CT data. \*Statistically significant ( $p < 0.05$ ).

**Abbreviations:** OR, odds ratio; CI, confidence interval; n, number; AChR, acetylcholine receptor; SD, standard deviation.

The authors apologize for the errors and advise they do not affect the conclusions of the study.

## Clinical Ophthalmology

Dovepress

### Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-ophthalmology-journal>